NEW YORK,
June 19, 2017
/PRNewswire/ -- WeissLaw LLP announced that a class action
was commenced in the United States District Court for the Northern
District of California on behalf
of shareholders of Nexvet Biopharma Public Limited Company
("Nexvet") (NASDAQ: NVET) seeking to pursue remedies under the
Securities and Exchange Act of 1934 (the "Exchange Act") in
connection with the proposed acquisition of Nexvet by Zoetis Inc.
("Zoetis").
On April 13, 2017, Nexvet
and Zoetis issued a joint press releases announcing that they had
entered into a definitive agreement pursuant to which Zoetis would
acquire all of the outstanding shares of Nexvet common stock for
$6.72 in cash for each share of
Nexvet common stock ("Proposed Transaction"). The complaint seeks
injunctive relief on behalf of the named plaintiff and all Nexvet
shareholders. The plaintiff is represented by WeissLaw, which has
expertise in prosecuting investor class actions and extensive
experience in actions involving financial fraud.
The complaint alleges that in an attempt to secure
shareholder approval for the merger, the defendants filed
materially false and/or misleading statements with the SEC in
violation of the Exchange Act. The omitted and/or misrepresented
information is believed to be material to Nexvet shareholders'
ability to make an informed decision whether to approve the
Proposed Transaction.
If you wish to serve as lead plaintiff, you must move the
Court no later than sixty days from today. If you wish to discuss
this action or have any questions concerning this notice or your
rights or interests, please contact plaintiff's counsel,
Joshua M. Rubin of WeissLaw at
888.593.4771, or by e-mail at stockinfo@weisslawllp.com. Any
member of the putative class may move the Court to serve as lead
plaintiff through counsel of their choice, or may choose to do
nothing and remain an absent class member.
WeissLaw LLP has litigated hundreds of stockholder class
and derivative actions for violations of corporate and fiduciary
duties. We have recovered over a billion dollars for defrauded
clients and obtained important corporate governance relief in many
of these cases. If you have information or would like legal advice
concerning possible corporate wrongdoing please email us at
stockinfo@weisslawllp.com.
Contact:
WeissLaw
LLP
Joshua M.
Rubin
1500 Broadway, 16th
Floor
New York,
NY
10036
212.682.3025
www.weisslawllp.com
stockinfo@weisslawllp.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/weisslaw-llp-files-class-action-lawsuit-against-nexvet-biopharma-plc-300476108.html
SOURCE WeissLaw LLP